πŸ‡ΊπŸ‡Έ FDA
Patent

US 10822426

Humanized anti-CD73 antibodies

granted A61PA61P35/00

Quick answer

US patent 10822426 (Humanized anti-CD73 antibodies) held by Corvus Pharmaceuticals, Inc. expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corvus Pharmaceuticals, Inc.
Grant date
Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61P, A61P35/00